{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T22:38:22Z","timestamp":1786747102741,"version":"build-2736575974"},"reference-count":53,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T00:00:00Z","timestamp":1689206400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Malignant melanoma is a highly aggressive cancer that spreads and metastasizes quickly. In recent years, the antiangiogenic drug bevacizumab has been trialed to treat malignant melanoma. We conducted the first meta-analysis to examine the efficacy and safety of bevacizumab combined with other drugs in malignant melanoma.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> We searched for randomized controlled trials (RCTs) and non-comparative clinical studies of bevacizumab combined with chemotherapy, targeted medicine, and interferon to treat malignant melanoma in PubMed, Embase, the Cochrane Library, and Web of Science. Meta-analysis of RCT was performed using Review Manager (version 5.4), and non-comparative meta-analysis was performed using R (version 4.0.3). The primary outcome was the objective response rate. Depending on the heterogeneity of the included studies, the pooled outcomes and 95% CI were calculated using either random-effects or fixed-effect models. Subgroup outcomes were calculated with possible relevant variables. Sensitivity analyses were carried out by excluding each study from the highly heterogeneous pooled results in turn. Funnel plot and Begg\u2019s test were used to test the included studies' potential publication bias. The level of significance was set at <jats:italic>p<\/jats:italic> &amp;lt; 0.05.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> This meta-analysis included 20 trials: five RCTs and 15 non-comparative clinical studies with a total of 23 bevacizumab intervention arms. In 14 treatment arms, bevacizumab was combined with chemotherapy drugs such as fotemustine, dacarbazine, carboplatin\/paclitaxel, and temozolomide. In six treatment arms, bevacizumab was combined with targeted medicines such as imatinib, everolimus, sorafenib, erlotinib, and temsirolimus. There were also six treatment arms that used bevacizumab in combination with interferon. The pooled objective response rate was 15.8% (95% CI, 11.4%\u201320.2%). Bevacizumab plus carboplatin\/paclitaxel significantly increased the overall survival compared to carboplatin\/paclitaxel (HR = 0.64, 95% CI, 0.49-0.85, <jats:italic>p<\/jats:italic> &amp;lt; 0.01). Fatigue, nausea, leukopenia, thrombocytopenia, and neutropenia were the most common adverse events. The pooled incidence of hypertension of all bevacizumab arms in malignant melanoma was 32.4% (95% CI, 24.5%\u201340.3%).<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> This study showed that bevacizumab combined with chemotherapy might be effective and well-tolerated in patients with stage III or IV unresectable malignant melanoma.<\/jats:p><jats:p><jats:bold>Systematic Review Registration<\/jats:bold>: [<jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/display_record.php?RecordID=304625<\/jats:ext-link>], identifier [CRD42022304625].<\/jats:p>","DOI":"10.3389\/fphar.2023.1163805","type":"journal-article","created":{"date-parts":[[2023,7,14]],"date-time":"2023-07-14T01:56:33Z","timestamp":1689299793000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Efficacy and safety of bevacizumab in patients with malignant melanoma: a systematic review and PRISMA-compliant meta-analysis of randomized controlled trials and non-comparative clinical studies"],"prefix":"10.3389","volume":"14","author":[{"given":"Xiao","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pu","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dandan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinzi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinpei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiting","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,7,13]]},"reference":[{"key":"B2","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1097\/00008390-199908000-00006","article-title":"Expression of basic fibroblast growth factor and vascular endothelial growth factor in primary and metastatic melanoma from the same patients","volume":"9","author":"Birck","year":"1999","journal-title":"Melanoma Res."},{"key":"B1","unstructured":"Genomic classification of cutaneous melanoma1681169610.1016\/j.cell.2015.05.044Cell.1612015"},{"key":"B3","doi-asserted-by":"publisher","first-page":"159","DOI":"10.3978\/j.issn.2304-3865.2012.07.01","article-title":"Guidelines for diagnosis and treatment of melanoma in China (2011 edition)","volume":"17","year":"2012","journal-title":"Chin. Clinl Oncol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1038\/mt.2013.79","article-title":"A phase II, randomized, double-blind, placebo-controlled multicenter trial of Endostar in patients with metastatic melanoma","volume":"21","author":"Cui","year":"2013","journal-title":"Mol. Ther."},{"key":"B5","doi-asserted-by":"publisher","first-page":"e761","DOI":"10.1097\/IJ9.0000000000000076","article-title":"Real-world clinical outcomes of anticancer treatments in patients with advanced melanoma in China: Retrospective, observational study","volume":"4","author":"Cui","year":"2019","journal-title":"IJS Oncol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"5862","DOI":"10.1158\/1078-0432.CCR-10-2363","article-title":"Bevacizumab plus fotemustine as first-line treatment in metastatic melanoma patients: Clinical activity and modulation of angiogenesis and lymphangiogenesis factors","volume":"16","author":"Del Vecchio","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"B7","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/nrd1381","article-title":"Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer","volume":"3","author":"Ferrara","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"B8","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1097\/CMR.0000000000000146","article-title":"Dacarbazine in combination with bevacizumab for the treatment of unresectable\/metastatic melanoma: A phase II study","volume":"25","author":"Ferrucci","year":"2015","journal-title":"Melanoma Res."},{"key":"B9","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1634\/theoncologist.2015-0108","article-title":"Phase I\/II trial of imatinib and bevacizumab in patients with advanced melanoma and other advanced cancers","volume":"20","author":"Flaherty","year":"2015","journal-title":"Oncologist"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","article-title":"Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations","volume":"367","author":"Flaherty","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1634\/theoncologist.2010-0190","article-title":"Systematic review of medical treatment in melanoma: Current status and future prospects","volume":"16","author":"Garbe","year":"2011","journal-title":"Oncologist"},{"key":"B12","doi-asserted-by":"publisher","first-page":"102017","DOI":"10.1016\/j.ctrv.2020.102017","article-title":"Bevacizumab (avastin) in cancer treatment: A review of 15 years of clinical experience and future outlook","volume":"86","author":"Garcia","year":"2020","journal-title":"Cancer Treat. Rev."},{"key":"B13","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1097\/CJI.0b013e31821dcefd","article-title":"A phase 2 trial of bevacizumab and high-dose interferon alpha 2B in metastatic melanoma","volume":"34","author":"Grignol","year":"2011","journal-title":"J. Immunother."},{"key":"B14","doi-asserted-by":"publisher","first-page":"322","DOI":"10.3978\/j.issn.2305-5839.2015.12.23","article-title":"Chinese guidelines on the diagnosis and treatment of melanoma (2015 edition)","volume":"3","author":"Guo","year":"2015","journal-title":"Ann. Transl. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2904","DOI":"10.1200\/JCO.2010.33.9275","article-title":"Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification","volume":"29","author":"Guo","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"4122","DOI":"10.1002\/cncr.25320","article-title":"Bevacizumab and everolimus in the treatment of patients with metastatic melanoma: A phase 2 trial of the sarah cannon Oncology research consortium","volume":"116","author":"Hainsworth","year":"2010","journal-title":"Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomised controlled trial","volume":"380","author":"Hauschild","year":"2012","journal-title":"Lancet"},{"key":"B18","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"B19","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1158\/2326-6066.CIR-14-0053","article-title":"Bevacizumab plus ipilimumab in patients with metastatic melanoma","volume":"2","author":"Hodi","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMOA032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1200\/JCO.2011.39.4767","article-title":"Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: Calgb 90401","volume":"30","author":"Kelly","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1200\/JCO.2011.34.6270","article-title":"Beam: A randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma","volume":"30","author":"Kevin","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1002\/cncr.27760","article-title":"A randomized phase 2 study of temozolomide and bevacizumab or nab\u2010paclitaxel, carboplatin, and bevacizumab in patients with unresectable stage IV melanoma: A north central cancer treatment group study, N0775","volume":"119","author":"Kottschade","year":"2013","journal-title":"Cancer"},{"key":"B24","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1200\/JCO.2010.30.2729","article-title":"Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme","volume":"29","author":"Lai","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined Nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"S24","DOI":"10.1097\/00008390-199706001-00081","article-title":"Biochemotherapy studies in the treatment of advanced melanoma: 081","volume":"24","author":"Legha","year":"1997","journal-title":"Semin. Oncol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s00280-014-2479-8","article-title":"Phase II study evaluating the efficacy, safety, and pharmacodynamic correlative study of dual antiangiogenic inhibition using bevacizumab in combination with sorafenib in patients with advanced malignant melanoma","volume":"74","author":"Mahalingam","year":"2014","journal-title":"Cancer Chemother. Pharmacol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"680407","DOI":"10.3389\/fimmu.2021.680407","article-title":"Immunotherapy in acral and mucosal melanoma: Current status and future directions","volume":"12","author":"Mao","year":"2021","journal-title":"Front. Immunol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1002\/cncr.31072","article-title":"NCCTG N0879 (alliance): A randomized phase 2 cooperative group trial of carboplatin, paclitaxel, and bevacizumab \u00b1 everolimus for metastatic melanoma","volume":"124","author":"McWilliams","year":"2018","journal-title":"Cancer"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.1056\/NEJMoa072113","article-title":"Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer","volume":"357","author":"Miller","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/pcmr.12394","article-title":"A phase II trial of erlotinib and bevacizumab for patients with metastatic melanoma","volume":"29","author":"Mudigonda","year":"2016","journal-title":"Pigment. Cell. melanoma Res."},{"key":"B32","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1002\/cncr.23987","article-title":"Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma: A north central cancer treatment group study, N047A","volume":"115","author":"Perez","year":"2009","journal-title":"Cancer"},{"key":"B33","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1634\/theoncologist.2015-0501","article-title":"Phase II trial of bevacizumab in combination with temozolomide as first-line treatment in patients with metastatic uveal melanoma","volume":"21","author":"Piperno-Neumann","year":"2016","journal-title":"Oncologist"},{"key":"B35","doi-asserted-by":"publisher","first-page":"5449","DOI":"10.1158\/1078-0432.CCR-18-1543","article-title":"The intersection between tumor angiogenesis and immune suppression","volume":"25","author":"Rahma","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"B36","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1200\/JCO.2009.26.5561","article-title":"Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: Final results of CALGB 90206","volume":"28","author":"Rini","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel\u2013carboplatin alone or with bevacizumab for non\u2013small-cell lung cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"e38364","DOI":"10.1371\/journal.pone.0038364","article-title":"Clinical efficacy and safety of bevacizumab monotherapy in patients with metastatic melanoma: Predictive importance of induced early hypertension","volume":"7","author":"Schuster","year":"2012","journal-title":"PLoS One"},{"key":"B39","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1586\/era.09.40","article-title":"Novel therapeutics for melanoma","volume":"9","author":"Seetharamu","year":"2009","journal-title":"Expert Rev. Anticancer Ther."},{"key":"B40","doi-asserted-by":"publisher","first-page":"9511","DOI":"10.1200\/JCO.2021.39.15_suppl.9511","article-title":"Atezolizumab in combination with bevacizumab in patients with unresectable locally advanced or metastatic mucosal melanoma: Interim analysis of an open-label phase II trial","volume":"39","author":"Si","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ejca.2020.04.044","article-title":"Open-label, phase IIa study of dabrafenib plus trametinib in East Asian patients with advanced BRAF V600-mutant cutaneous melanoma","volume":"135","author":"Si","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"B42","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1186\/s12885-018-4336-3","article-title":"Vemurafenib in Chinese patients with BRAFV600 mutation-positive unresectable or metastatic melanoma: An open-label, multicenter phase I study","volume":"18","author":"Si","year":"2018","journal-title":"BMC Cancer"},{"key":"B43","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","article-title":"Methodological index for non\u2010randomized studies (MINORS): Development and validation of a new instrument","volume":"73","author":"Slim","year":"2003","journal-title":"ANZ J. Surg."},{"key":"B44","doi-asserted-by":"publisher","first-page":"3611","DOI":"10.1158\/1078-0432.CCR-12-3919","article-title":"Clinical activity and safety of combination therapy with temsirolimus and bevacizumab for advanced melanoma: A phase II trial (CTEP 7190\/mel47)","volume":"19","author":"Slingluff","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"B45","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1097\/COC.0b013e318287bbae","article-title":"Phase II study of nab-paclitaxel and bevacizumab as first-line therapy for patients with unresectable stage III and IV melanoma","volume":"38","author":"Spitler","year":"2015","journal-title":"Am. J. Clin. Oncol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"4250","DOI":"10.1158\/1078-0432.CCR-19-3922","article-title":"Safety, efficacy, and biomarker analysis of Toripalimab in previously treated advanced melanoma: Results of the POLARIS-01 multicenter phase II trial","volume":"26","author":"Tang","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"B47","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1200\/JCO.2001.19.2.577","article-title":"Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival","volume":"19","author":"Ugurel","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"B48","unstructured":"Nab-paclitaxel and bevacizumab or ipilimumab as first-line therapy in treating patients with stage IV melanoma that cannot Be removed by surgery2018"},{"key":"B49","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1245\/s10434-007-9389-5","article-title":"A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma","volume":"14","author":"Varker","year":"2007","journal-title":"Ann. Surg. Oncol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1097\/CMR.0b013e3283390365","article-title":"A phase II trial of bevacizumab with dacarbazine and daily low-dose interferon-alpha2a as first line treatment in metastatic melanoma","volume":"20","author":"Vihinen","year":"2010","journal-title":"Melanoma Res."},{"key":"B51","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1093\/annonc\/mdr126","article-title":"First-line temozolomide combined with bevacizumab in metastatic melanoma: A multicentre phase II trial (SAKK 50\/07)","volume":"23","author":"Von Moos","year":"2012","journal-title":"Ann. Oncol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1097\/00008390-200510000-00015","article-title":"Phase II trial of weekly paclitaxel in patients with advanced melanoma","volume":"15","author":"Walker","year":"2005","journal-title":"Melanoma Res."},{"key":"B53","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1200\/JCO.20.00902","article-title":"Randomized phase II study of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced mucosal melanoma","volume":"39","author":"Yan","year":"2021","journal-title":"J. Clin. Oncol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1163805\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,14]],"date-time":"2023-07-14T01:56:39Z","timestamp":1689299799000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1163805\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,13]]},"references-count":53,"alternative-id":["10.3389\/fphar.2023.1163805"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1163805","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,13]]},"article-number":"1163805"}}